Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) is now available.
Japan Tissue Engineering Co., Ltd. has announced a business plan outlining measures for growth and addressing market environment and risks. The company is poised to enhance its operations and industry positioning by leveraging its expertise in regenerative medicine, which could have significant implications for stakeholders, including advancements in medical treatments and potential market expansion.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates in the regenerative medicine industry, focusing on the development and commercialization of autologous cultured tissues. Their primary products include JACE, JACEMIN, JACC, NEPIC, and OCURAL, which are regenerative medical products derived from patients’ own tissues. The company also offers LabCyte, a cultured human tissue for research purposes, providing an alternative to animal testing.
Average Trading Volume: 305,795
Technical Sentiment Signal: Buy
Current Market Cap: Yen23.88B
Learn more about 7774 stock on TipRanks’ Stock Analysis page.